Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance

Regeneron Pharmaceuticals IncTrade
Vanguard Emerging Markets Stock Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.97. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals.

REGNVWO
Market Cap
$83.43B
Sector
Health
52-Week High
$852.03$61.44
52-Week Low
$555.51$52.42
Enterprise Value
$78.14B
Dividend Yield
0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Vanguard Emerging Markets Stock Index Fund ETF

VWO trades at $61.245, down 0.32% on the day, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with multiple firms increasing stakes recently. News highlights robust emerging markets performance and record capital inflows, though expense ratios and China exposure remain focal points for investors.

The outlook for VWO is positive given institutional buying and favorable EM trends, but risks include currency volatility and concentrated country weights. Upside hinges on sustained EM outperformance versus developed markets, while any China downturn could pressure returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN

About Vanguard Emerging Markets Stock Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.

Read more on VWO